Arctic Bioscience – Strengthening IP platform with new patent for method for utilizing immature herring roe

Report this content

Arctic Bioscience, a biotech company with a pre-commercial pharmaceutical business and a commercial nutraceutical business, is pleased to announce it is granted a U.S. patent1 with a new method related to type II diabetes. The patent claims protection for a method utilizing a lipid composition with a phospholipid extract from immature herring roe. The method is based on the same patented technology that is being used in the company’s two ongoing development programs for psoriasis and brain development.

Arctic Biosciences pharmaceutical development programs are based on the company’s proprietary technology utilizing a lipid composition with a phospholipid extract from immature herring roe. Building a portfolio of patents for various utilizations of our technology and methods is an important part of our strategy to strengthen our IP platform to safeguard ongoing development programs for existing and new drug candidates.” says CEO Ole Arne Eiksund.

Arctic Bioscience’s drug candidate for treatment of mild-to-moderate psoriasis, HRO350, contains substances with the potential to affect cellular processes, with anecdotal evidence supporting relevance in inflammatory conditions. As such, market potential for our platform technology is significant, potentially opening large addressable markets.

In addition to protecting ongoing and future development programs, securing exclusive rights for utilisation of the technology in core and adjacent areas may represent opportunities for new business areas for Arctic Bioscience in the future.  Diabetes type II is a major global health challenge.

Going forward, Arctic Bioscience’s focus will remain on the upcoming phase II study for psoriasis where the unmet need continues to be high and the market opportunity attractive. The company has also an ongoing collaboration with Smerud Medical Research to develop a new novel drug candidate for brain development in extremely premature infants, also based on our existing technology platform.

For more information, please contact

Ole Arne Eiksund

CEO Arctic Bioscience

Phone: +47 908 43 944

Danielle Glenn

CFO Arctic Bioscience

Phone: +47 909 98 201

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing nutraceutical products based on herring roe oil. Herring roe oil contains lipids that are essential to maintain cell membranes, contributing to normal functioning of brain, heart, and vision. Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients to other companies making dietary supplements, and as finished goods under the Romega brand. The strategy is to switch sales from bulk to finished goods and focus markets are USA and China.

The company is developing HRO350 – a novel investigational drug candidate with herring roe as raw material. HRO350 is being developed for treatment of mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile. Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.


  1. U.S. patent number 11,135,230B2